MCID: GNG004
MIFTS: 53

Ganglioglioma

Categories: Cancer diseases, Neuronal diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ganglioglioma

MalaCards integrated aliases for Ganglioglioma:

Name: Ganglioglioma 11 19 58 75 53 5 43 14 38 16 71
Childhood Ganglioglioma 11 5 71
Adult Ganglioglioma 11 71
Mixed Cell Tumors Containing Both Neural Ganglionic Cells and Neural Glial Cell Components 19
Cns Ganglioglioma 11

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:5078
MeSH 43 D018303
SNOMED-CT 68 87191000119100
UMLS via Orphanet 72 C0206716
Orphanet 58 ORPHA251949
UMLS 71 C0206716 C1332202 C1332969

Summaries for Ganglioglioma

GARD: 19 A Ganglioglioma is a rare type of brain tumor, accounting for approximately 1% of all brain tumors. Gangliogliomas occur when a single cell in the brain starts to divide into more cells, forming a tumor. This can occur when the cell randomly acquires changes in genes that regulate how a cell divides. Most Gangliogliomas grow slowly and are considered benign. However, up to 10% of Gangliogliomas may grow more rapidly and become malignant, meaning the tumor affects the surrounding brain tissue.

MalaCards based summary: Ganglioglioma, also known as childhood ganglioglioma, is related to gangliocytoma and intracranial hypertension, and has symptoms including seizures An important gene associated with Ganglioglioma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Signal Transduction and Endometrial cancer. The drugs Dabrafenib and Trametinib have been mentioned in the context of this disorder. Affiliated tissues include temporal lobe, brain and spinal cord, and related phenotypes are no effect and no effect

Orphanet: 58 Ganglioglioma is a rare, usually benign, well-circumscribed, often cystic, mixed neuronal-glial tumor (composed of both neoplastic glial and ganglionic elements) which is typically located in the temporal lobe and rarely invades the surrounding tissue. Patients usually present with seizures refractory to medical treatment. Association with neurofibromatosis type I and tuberous sclerosis has been reported.

Disease Ontology: 11 A cell type benign neoplasm that has material basis in glial-type cells.

Wikipedia: 75 Ganglioglioma is a rare, slow-growing primary central nervous system (CNS) tumor which most frequently... more...

Related Diseases for Ganglioglioma

Diseases related to Ganglioglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 550)
# Related Disease Score Top Affiliating Genes
1 gangliocytoma 31.8 TSC2 SYP GFAP ENO2 CHGA
2 intracranial hypertension 30.6 S100B GFAP ENO2
3 rhabdoid cancer 30.6 TP53 SYP SMARCB1
4 pleomorphic xanthoastrocytoma 30.6 TP53 SYP NF1 H3-3A BRAF
5 dysembryoplastic neuroepithelial tumor 30.5 SYP NF1 H3-3A GFAP
6 hydrocephalus 30.5 TP53 SYP SMARCB1 S100B NES GFAP
7 cellular ependymoma 30.3 SYP S100B NES GFAP
8 chiari malformation 30.1 SYP MAP2 GFAP
9 neurofibroma 30.1 TP53 SYP S100B NF1
10 adenoma 30.1 TP53 SYP CHGA CCND1 BRAF
11 syringomyelia 30.0 NF1 NES GFAP
12 cerebellar liponeurocytoma 30.0 SYP MAP2 ENO2
13 rhabdoid meningioma 30.0 SYP SMARCB1 GFAP
14 pilocytic astrocytoma of cerebellum 30.0 NF1 H3-3A BRAF
15 anaplastic oligodendroglioma 30.0 TP53 NF1 NES H3-3A GFAP
16 islet cell tumor 30.0 SYP ENO2 CHGA
17 congenital heart defects, hamartomas of tongue, and polysyndactyly 30.0 TSC2 TSC1
18 anaplastic ependymoma 29.9 SYP SMARCB1 S100B H3-3A GFAP
19 oligodendroglioma 29.9 TP53 SYP S100B NF1 GFAP ENO2
20 mixed cell type cancer 29.9 TP53 SYP ENO2 CHGA
21 benign teratoma 29.9 TP53 SYP ENO2 CHGA
22 hemangioblastoma 29.9 SYP S100B GFAP ENO2
23 lung benign neoplasm 29.9 TP53 SYP ENO2 CHGA
24 peutz-jeghers syndrome 29.9 TSC2 TSC1 TP53
25 diffuse astrocytoma 29.9 TP53 NF1 H3-3A GFAP
26 central neurocytoma 29.9 SYP NES MAP2 GFAP ENO2 CHGA
27 neurofibromatosis, type i 29.8 TSC2 TSC1 TP53 S100B NF1 ENO2
28 cowden syndrome 29.8 TSC2 TSC1 TP53 NF1
29 tuberous sclerosis 1 29.8 TSC2 TSC1
30 focal epilepsy 29.8 TSC1 SLC1A2 PVALB GFAP
31 basal cell carcinoma 29.7 TP53 SYP NES ENO2 CHGA
32 mesenchymal cell neoplasm 29.7 TP53 SMARCB1 NF1
33 anaplastic astrocytoma 29.7 TP53 NF1 NES H3-3A GFAP CCND1
34 stroke, ischemic 29.7 TH SLC1A2 NES MAP2 ENO2
35 glioblastoma 29.7 TSC2 TP53 NF1 NES MYCN H3-3A
36 epilepsy 29.6 TSC2 TSC1 SLC1A2 S100B PVALB NES
37 cowden syndrome 1 29.6 TSC2 TSC1 TP53 NSD1 NF1
38 pilocytic astrocytoma 29.6 TSC1 TP53 SYP S100B NF1 NES
39 status epilepticus 29.6 SLC1A2 S100B PVALB GFAP ENO2
40 neurilemmoma 29.5 SYP SMARCB1 S100B NF1 NES GFAP
41 hemangioma 29.5 TSC2 TSC1 TP53 SYP ENO2 CHGA
42 lynch syndrome 29.5 TP53 NF1 CCND1 BRAF
43 obstructive hydrocephalus 29.5 TSC2 TSC1 SYP NF1 H3-3A GFAP
44 ganglioneuroblastoma 29.5 TH SYP S100B MYCN ENO2 CHGA
45 atypical teratoid rhabdoid tumor 29.4 TP53 SYP SMARCB1 NF1 MYCN H3-3A
46 giant cell glioblastoma 29.4 TP53 SYP NF1 MYCN H3-3A GFAP
47 diffuse midline glioma, h3 k27m-mutant 29.4 TP53 NF1 NES MYCN H3-3A
48 spinal cancer 29.4 SMARCB1 NF1 H3-3A GFAP ENO2
49 neuroendocrine tumor 29.4 SYP NF1 ENO2 CHGA CCND1
50 brain cancer 29.3 TSC1 TP53 SYP SMARCB1 NF1 NES

Graphical network of the top 20 diseases related to Ganglioglioma:



Diseases related to Ganglioglioma

Symptoms & Phenotypes for Ganglioglioma

UMLS symptoms related to Ganglioglioma:


seizures

GenomeRNAi Phenotypes related to Ganglioglioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 BRAF CCND1 CHGA ENO2 GFAP H3-3A
2 no effect GR00402-S-2 10.18 BRAF CHGA H3-3A MAP2 MYCN NES
3 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.55 BRAF ENO2 MYCN TSC1 TSC2
4 Decreased viability in pancreas lineage GR00235-A 9.26 CCND1 MAP2 PVALB TP53

MGI Mouse Phenotypes related to Ganglioglioma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.48 BRAF CCND1 CHGA ENO2 GFAP MAP2
2 homeostasis/metabolism MP:0005376 10.4 BRAF CCND1 CHGA GFAP H3-3A MYCN
3 growth/size/body region MP:0005378 10.38 BRAF CCND1 CHGA ENO2 GFAP H3-3A
4 normal MP:0002873 10.37 BRAF CCND1 GFAP H3-3A MYCN NF1
5 behavior/neurological MP:0005386 10.32 BRAF CCND1 ENO2 GFAP H3-3A MAP2
6 cellular MP:0005384 10.31 BRAF CCND1 ENO2 GFAP H3-3A MYCN
7 renal/urinary system MP:0005367 10.24 BRAF CHGA H3-3A MYCN NF1 PVALB
8 muscle MP:0005369 10.18 BRAF CHGA GFAP MYCN NF1 PVALB
9 cardiovascular system MP:0005385 10.18 BRAF CCND1 CHGA GFAP MYCN NF1
10 neoplasm MP:0002006 10.17 BRAF CCND1 NF1 SMARCB1 TH TP53
11 embryo MP:0005380 10.16 BRAF H3-3A MYCN NES NF1 NSD1
12 liver/biliary system MP:0005370 10.11 BRAF MYCN NF1 SMARCB1 TH TP53
13 reproductive system MP:0005389 10 BRAF CCND1 CHGA H3-3A MAP2 MYCN
14 respiratory system MP:0005388 9.92 BRAF CCND1 ENO2 MYCN NF1 TH
15 mortality/aging MP:0010768 9.89 BRAF CCND1 CHGA GFAP H3-3A MAP2
16 vision/eye MP:0005391 9.85 BRAF CCND1 GFAP MYCN NF1 PVALB
17 integument MP:0010771 9.28 BRAF CCND1 NF1 S100B SMARCB1 TH

Drugs & Therapeutics for Ganglioglioma

Drugs for Ganglioglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
2
Trametinib Approved Phase 4 871700-17-3 11707110
3 Protein Kinase Inhibitors Phase 4
4
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
5
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
6
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
7 Protective Agents Phase 2
8 Antioxidants Phase 2
9 Tubulin Modulators Phase 2
10 Antimitotic Agents Phase 2
11
Bevacizumab Approved, Investigational Phase 1 216974-75-3 135329020
12
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
13
Lenograstim Approved, Investigational Phase 1 135968-09-1
14
Gemcitabine Approved Phase 1 95058-81-4, 122111-03-9 60750
15
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
16 Antineoplastic Agents, Immunological Phase 1
17 Angiogenesis Inhibitors Phase 1
18 topoisomerase I inhibitors Phase 1
19 Antiviral Agents Phase 1
20 Anti-Infective Agents Phase 1
21 Antimetabolites Phase 1
22 Immunosuppressive Agents Phase 1
23 Immunologic Factors Phase 1
24 Antineoplastic Agents, Alkylating Phase 1
25 Anesthetics Phase 1
26 Antirheumatic Agents Phase 1
27 Alkylating Agents Phase 1

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) Recruiting NCT03919071 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
3 Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) Active, not recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
4 A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes Active, not recruiting NCT01288235 Phase 2
5 Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study Completed NCT01999270 Phase 1 Irinotecan;Bevacizumab
6 Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma Recruiting NCT03434262 Phase 1 Gemcitabine;ribociclib;sonidegib;trametinib
7 A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide Active, not recruiting NCT03152318 Phase 1 rQNestin;Cyclophosphamide
8 Astrocytoma / Desmoplastic Gamliogliomes (DIA / DIG) - Study of the French Cohort of the Last 20 Years : Clinical, Anatomopathological, Molecular and Radiological Charactersics Unknown status NCT03115164
9 Intraoperative Fluorescence of Gangliogliomas and Neuroepithelial Dysembryoplastic Tumors Completed NCT03970785
10 Defining Personal and Communal Aspects of Social Determinants of Health in Glioblastoma Population Recruiting NCT03900689
11 Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology Recruiting NCT04648462
12 A Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma Recruiting NCT04065776

Search NIH Clinical Center for Ganglioglioma

Cochrane evidence based reviews: ganglioglioma

Genetic Tests for Ganglioglioma

Anatomical Context for Ganglioglioma

Organs/tissues related to Ganglioglioma:

MalaCards : Temporal Lobe, Brain, Spinal Cord, Medulla Oblongata, Pineal, Cerebellum, Parietal Lobe

Publications for Ganglioglioma

Articles related to Ganglioglioma:

(show top 50) (show all 1177)
# Title Authors PMID Year
1
The reelin pathway components disabled-1 and p35 in gangliogliomas--a mutation and expression analysis. 53 62
15175076 2004
2
Mutational analysis of TSC1 and TSC2 genes in gangliogliomas. 53 62
11437991 2001
3
Tuberin expression in ganglioglioma. 53 62
10808554 2000
4
alpha-Synuclein is expressed in a variety of brain tumors showing neuronal differentiation. 53 62
10672322 2000
5
Synaptophysin staining for ganglioglioma. 53 62
10219424 1999
6
The significance of immunocytochemical markers, synaptophysin and neurofilaments in diagnosis of ganglioglioma. 53 62
10581850 1999
7
Mixed dysembryoplastic neuroepithelial tumor and ganglioglioma. 53 62
9650758 1998
8
Immunohistochemical expression of tyrosine kinase (Trk) receptor proteins in mature neuronal cell tumors of the central nervous system. 53 62
9625303 1998
9
Synaptophysin staining in normal brain: importance for diagnosis of ganglioglioma. 53 62
9591724 1998
10
Pleomorphic xanthoastrocytoma with gangliogliomatous component. 53 62
9521020 1997
11
Rapid growth of an optic nerve ganglioglioma in a patient with neurofibromatosis 1. 53 62
8637690 1996
12
Central nervous system gangliogliomas. Part 1: Pathology. 53 62
8246054 1993
13
Immunohistochemistry of synapsin I and synaptophysin in human nervous system and neuroendocrine tumors. Applications in diagnostic neuro-oncology. 53 62
8287627 1993
14
Parvalbumin and calbindin D-28K immunoreactivity in central ganglioglioma and dysplastic gangliocytoma of the cerebellum. Report of two cases. 53 62
8416231 1993
15
A clinicopathologic and immunomorphologic study of 13 cases of ganglioglioma. 53 62
1913457 1991
16
Peritoneal metastasis of a brainstem anaplastic ganglioglioma in a 2-year-old boy: case report and literature review. 62
35389065 2022
17
ALL-481 Infant Cancer in Armenia: Nationwide Survey for the Period of 1995-2021. 62
36163751 2022
18
Ganglioglioma revealed by spontaneous intracerebral hematoma: A cohort study. 62
35257724 2022
19
Sudden Unexpected Death in Epilepsy: A Report of Three Commonly Encountered Anatomic Findings in the Forensic Setting With Recommendations for Best Practices. 62
35642769 2022
20
Cytologic and histologic features of pigmented pleomorphic xanthoastrocytoma: A case report and literature review. 62
35429149 2022
21
Teratoma With Malignant Ectomesenchymoma in the Pineal Region: A Case Report. 62
36081970 2022
22
Anaplastic ganglioglioma-A diagnosis comprising several distinct tumour types. 62
35977725 2022
23
MR Imaging Characteristics and ADC Histogram Metrics for Differentiating Molecular Subgroups of Pediatric Low-Grade Gliomas. 62
36007944 2022
24
Transformation of ganglioglioma to epithelioid glioblastoma, both with BRAF V600E mutation. 62
34895740 2022
25
Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma. 62
35703914 2022
26
Treatment Limitations for Pediatric Diffuse Intrinsic Pontine Gliomas in a Middle-Income Country. 62
35945995 2022
27
The landscape of common genetic drivers and DNA methylation in low-grade (epilepsy-associated) neuroepithelial tumors: A review. 62
35844095 2022
28
Gliosarcoma With Glioneuronal and Rhabdomyosarcoma Components. 62
35959193 2022
29
Anaplasia and age of onset in desmoplastic infantile ganglioglioma: Case report and review of the literature. 62
35670752 2022
30
A case of ganglioglioma grade 3 with H3 K27M mutation arising in the medial temporal lobe in an elderly patient. 62
35187715 2022
31
The molecular characteristics of low-grade and high-grade areas in desmoplastic infantile astrocytoma/ganglioglioma. 62
35191090 2022
32
Infratentorial ganglioglioma mimicking a cerebellar metastasis. 62
35633078 2022
33
An Endoscopic Transcortical-Transventricular Approach to Septum Pellucidum Ganglioglioma. 62
35864690 2022
34
Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss. 62
34865163 2022
35
Uncommon Glioneuronal Tumors: A Radiologic and Pathologic Synopsis. 62
35512827 2022
36
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. 62
34718782 2022
37
Upfront Molecular Targeted Therapy for the Treatment of BRAF-Mutant Pediatric High-Grade Glioma. 62
35397478 2022
38
Thalamic Tumors in a Pediatric Population: Surgical Outcomes and Utilization of High-Definition Fiber Tractography and the Fiber Tracking Technique. 62
35386482 2022
39
Ganglioglioma with novel molecular features presenting in a child with Allan-Herndon-Dudley syndrome. 62
35236707 2022
40
Radiological and clinical outcomes of stereotactic radiosurgery for gangliogliomas: an international multicenter study. 62
35334469 2022
41
Anaplastic gangliogliomas of the spinal cord: a scoping review of the literature. 62
34312775 2022
42
Low-grade epilepsy-associated neuroepithelial tumours with a prominent oligodendroglioma-like component: The diagnostic challenges. 62
34551121 2022
43
Rare simultaneous occurrence of a ganglioglioma and diffuse astrocytoma with distinct molecular features in a teenager with neurofibromatosis type 1. 62
35228248 2022
44
Optic Neuropathy Revealing Severe Superficial Siderosis in the Setting of Long-standing Low-grade Intracranial Neoplasm. 62
35574162 2022
45
Integrated genotype-phenotype analysis of long-term epilepsy-associated ganglioglioma. 62
34355449 2022
46
Rethinking the Management of Optic Pathway Gliomas: A Single Center Experience. 62
35784925 2022
47
Bilateral oligodendroglial hamartomas: A rare cause of drug-resistant epilepsy in a pediatric patient. 62
35673591 2022
48
From a dysembryoplastic neuroepithelial tumor to a glioblastoma multiforme: Pitfalls of initial diagnosis on biopsy material, a case report. 62
35242409 2022
49
Infantile Spasms, Clinical Manifestations of a Rare Brain Tumor: A Case Report and Literature Review. 62
35497104 2022
50
Establishment and Characterization of Brain Cancer Primary Cell Cultures From Patients to Enable Phenotypic Screening for New Drugs. 62
35370679 2022

Variations for Ganglioglioma

ClinVar genetic disease variations for Ganglioglioma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BRAF NM_004333.6(BRAF):c.1794_1796dup (p.Thr599dup) DUP Pathogenic
162793 rs727502902 GRCh37: 7:140453138-140453139
GRCh38: 7:140753338-140753339
2 NF1 NM_001042492.3(NF1):c.6852_6855del (p.Tyr2285fs) DEL Likely Pathogenic
216866 rs1555535032 GRCh37: 17:29665752-29665755
GRCh38: 17:31338734-31338737
3 BAP1 NM_004656.4(BAP1):c.1833G>C (p.Glu611Asp) SNV Uncertain Significance
620598 rs771494475 GRCh37: 3:52437211-52437211
GRCh38: 3:52403195-52403195

Cosmic variations for Ganglioglioma:

8 (show all 42)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149315872 ZFHX3 central nervous system,brain,other,ganglioglioma c.10376C>T p.P3459L 16:72787900-72787900 9
2 COSM102040939 ZFHX3 central nervous system,brain,other,ganglioglioma c.7634C>T p.P2545L 16:72787900-72787900 9
3 COSM87290663 ZFHX3 central nervous system,brain,other,ganglioglioma c.10376C>T p.P3459L 16:72787900-72787900 9
4 COSM133282459 IDH2 central nervous system,temporal lobe,other,ganglioglioma c.336G>A p.W112* 15:90088629-90088629 9
5 COSM136793306 IDH2 central nervous system,temporal lobe,other,ganglioglioma c.208-127G>A p.? 15:90088629-90088629 9
6 COSM89230121 IDH2 central nervous system,temporal lobe,other,ganglioglioma c.492G>A p.W164* 15:90088629-90088629 9
7 COSM130561817 C11orf65 central nervous system,brain,other,ganglioglioma c.641-8418C>G p.? 11:108317489-108317489 9
8 COSM131103045 BRCA2 central nervous system,brain,other,ganglioglioma c.9085G>A p.A3029T 13:32379881-32379881 9
9 COSM99025171 BRCA2 central nervous system,brain,other,ganglioglioma c.9085G>A p.A3029T 13:32379881-32379881 9
10 COSM149385292 BRAF central nervous system,brain,other,ganglioglioma c.1919T>A p.V640E 7:140753336-140753336 9
11 COSM88803061 BRAF central nervous system,brain,other,ganglioglioma c.1919T>A p.V640E 7:140753336-140753336 9
12 COSM150563774 BRAF central nervous system,brain,other,ganglioglioma c.1799T>A p.V600E 7:140753336-140753336 9
13 COSM118787231 BRAF central nervous system,brain,other,ganglioglioma c.1799T>A p.V600E 7:140753336-140753336 9
14 COSM114609379 ATM central nervous system,brain,other,ganglioglioma c.6315G>C p.R2105S 11:108317489-108317489 9
15 COSM88154796 ATM central nervous system,brain,other,ganglioglioma c.6315G>C p.R2105S 11:108317489-108317489 9
16 COSM102656129 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
17 COSM89046819 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
18 COSM105514140 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
19 COSM94463526 NF2 central nervous system,brain,other,neoplasm c.452A>G p.Y151C 22:29655652-29655652 3
20 COSM102848205 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
21 COSM93474794 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
22 COSM89067962 NF2 central nervous system,brain,other,neoplasm c.326A>G p.Y109C 22:29655652-29655652 3
23 COSM105111282 NF2 central nervous system,brain,other,neoplasm c.447+13367A>G p.? 22:29655652-29655652 3
24 COSM95502154 NF2 central nervous system,brain,other,neoplasm c.449A>G p.Y150C 22:29655652-29655652 3
25 COSM92446479 NF2 central nervous system,brain,other,neoplasm c.326A>G p.Y109C 22:29655652-29655652 3
26 COSM90465359 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
27 COSM112752230 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
28 COSM103033757 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
29 COSM103033796 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
30 COSM103034325 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
31 COSM112752272 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
32 COSM90465396 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
33 COSM90466087 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
34 COSM90465733 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
35 COSM112752610 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
36 COSM112752921 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
37 COSM112752563 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
38 COSM90465675 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
39 COSM103034038 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
40 COSM103034000 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
41 COSM93220513 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 6:108561791-108561791 3
42 COSM102860866 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 6:108561791-108561791 3

Expression for Ganglioglioma

Search GEO for disease gene expression data for Ganglioglioma.

Pathways for Ganglioglioma

Pathways related to Ganglioglioma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1 13.59 BRAF CCND1 GFAP H3-3A MYCN NF1
2
Show member pathways
12.57 BRAF CCND1 NF1 TP53 TSC2
3
Show member pathways
12.11 TSC2 TSC1 TP53 CCND1
4
Show member pathways
12.02 TSC2 TSC1 TP53 CCND1 BRAF
5
Show member pathways
12.01 TSC2 TSC1 TP53 CCND1
6 11.94 TSC2 TSC1 TP53 BRAF
7 11.91 BRAF CCND1 NF1 TP53 TSC1 TSC2
8
Show member pathways
11.85 TSC2 TSC1 NF1 BRAF
9 11.81 TH SYP SLC1A2 S100B NF1 MYCN
10 11.72 TSC2 TSC1 TP53
11 11.7 TSC2 TSC1 ENO2
12 11.69 TSC2 TSC1 TP53
13 11.59 TP53 TH CCND1
14 11.57 TSC2 TSC1 TP53 CCND1
15 11.54 TP53 NSD1 MYCN
16 11.53 TH SYP S100B NES MAP2 GFAP
17 11.49 TH NF1 CCND1
18
Show member pathways
11.45 TSC2 TSC1 NF1 BRAF
19 11.29 TP53 CCND1 BRAF
20 11.23 TSC2 TSC1 TP53 SMARCB1 H3-3A CCND1
21 11.19 TSC2 TSC1 TP53 MAP2
22 10.58 TP53 BRAF

GO Terms for Ganglioglioma

Cellular components related to Ganglioglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 TSC1-TSC2 complex GO:0033596 9.26 TSC2 TSC1
2 germ cell nucleus GO:0043073 8.92 TP53 SMARCB1

Biological processes related to Ganglioglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of mitophagy GO:1901525 9.56 TSC2 TP53
2 response to xenobiotic stimulus GO:0009410 9.56 TP53 TH SLC1A2 ENO2 CCND1
3 positive regulation of miRNA maturation GO:1903800 9.5 TP53 MYCN
4 D-aspartate import across plasma membrane GO:0070779 9.46 SLC1A2 GFAP
5 Schwann cell proliferation GO:0014010 8.92 NF1 GFAP

Sources for Ganglioglioma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....